CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Elicit Therapeutics Inc. - ELTX CFD

8.3554
2.33%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0692
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 8.1654
Open* 7.9754
1-Year Change* 919.09%
Day's Range* 7.9754 - 8.7554
52 wk Range 4.61-24.39
Average Volume (10 days) 400.64K
Average Volume (3 months) 1.70M
Market Cap 41.11M
P/E Ratio -100.00K
Shares Outstanding 8.41M
Revenue N/A
EPS -9.18
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 15, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 8.3554 0.3800 4.76% 7.9754 8.7954 7.9754
Apr 18, 2024 8.1654 -0.8300 -9.23% 8.9954 8.9954 7.8554
Apr 17, 2024 9.1454 -0.1700 -1.82% 9.3154 9.6754 8.4754
Apr 16, 2024 9.4454 0.2400 2.61% 9.2054 9.5454 9.2054
Apr 15, 2024 8.9554 -0.9200 -9.32% 9.8754 10.1754 8.5454
Apr 12, 2024 9.8254 0.7500 8.26% 9.0754 9.8254 9.0754
Apr 11, 2024 9.6454 0.9200 10.54% 8.7254 9.6454 8.4754
Apr 10, 2024 8.4754 -0.3000 -3.42% 8.7754 8.8754 8.3654
Apr 9, 2024 8.6354 -0.0900 -1.03% 8.7254 9.0354 8.3254
Apr 8, 2024 8.6354 -0.3000 -3.36% 8.9354 9.6554 8.2954
Apr 5, 2024 8.5654 1.2300 16.77% 7.3354 8.9154 7.3254
Apr 4, 2024 7.3454 0.0500 0.69% 7.2954 7.5254 7.1754
Apr 3, 2024 7.2754 -0.2000 -2.68% 7.4754 7.4854 6.8754
Apr 2, 2024 7.0754 0.0300 0.43% 7.0454 7.4054 6.6754
Apr 1, 2024 7.0854 -0.0100 -0.14% 7.0954 7.1454 6.5954
Mar 28, 2024 7.5754 0.1700 2.30% 7.4054 7.7654 7.2254
Mar 27, 2024 7.3154 0.6000 8.93% 6.7154 7.3654 6.7154
Mar 26, 2024 6.9554 0.0800 1.16% 6.8754 7.1354 6.2754
Mar 25, 2024 6.7554 0.1800 2.74% 6.5754 6.9354 6.5754
Mar 22, 2024 6.5854 0.1500 2.33% 6.4354 6.7954 6.4354

Elicit Therapeutics Inc. Events

Time (UTC) Country Event
Wednesday, May 8, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Elicio Therapeutics Inc Earnings Release
Q1 2024 Elicio Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Friday, August 9, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 Elicio Therapeutics Inc Earnings Release
Q2 2024 Elicio Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 2.301 28.312 2.88 1.487 4.029
Revenue 2.301 28.312 2.88 1.487 4.029
Cost of Revenue, Total 0 0.433 1.19 0.64 0.378
Gross Profit 2.301 27.879 1.69 0.847 3.651
Total Operating Expense 41.922 66.714 58.153 40.078 18.371
Selling/General/Admin. Expenses, Total 14.637 18.488 17.986 9.601 5.391
Research & Development 18.1 48.698 38.977 29.837 12.602
Operating Income -39.621 -38.402 -55.273 -38.591 -14.342
Interest Income (Expense), Net Non-Operating 0.719 -2.191 -8.249 0.488 0.401
Other, Net 0.095 -13.98 -16.527 -2.555 -6.084
Net Income Before Taxes -38.807 -54.573 -80.107 -40.658 -20.025
Net Income After Taxes -38.807 -54.573 -80.107 -40.658 -20.025
Net Income Before Extra. Items -38.807 -54.573 -80.107 -40.658 -20.025
Net Income -38.807 -54.573 -80.107 -40.658 -20.025
Total Adjustments to Net Income 0 -4.98
Income Available to Common Excl. Extra. Items -38.807 -54.573 -80.107 -40.658 -25.005
Income Available to Common Incl. Extra. Items -38.807 -54.573 -80.107 -40.658 -25.005
Diluted Net Income -38.807 -54.573 -80.107 -40.658 -25.005
Diluted Weighted Average Shares 3.00407 2.82448 1.47621 0.99763 0.99763
Diluted EPS Excluding Extraordinary Items -12.9181 -19.3214 -54.2652 -40.7544 -25.0643
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -9.86062 -19.6418 -54.2259 -40.7544 -25.0643
Gain (Loss) on Sale of Assets 0 -0.058
Unusual Expense (Income) 9.185 -0.905
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0.653
Revenue 0 0 0.653
Cost of Revenue, Total
Gross Profit
Total Operating Expense 7.173 7.805 7.051 9.05 9.688
Selling/General/Admin. Expenses, Total 2.833 2.321 3.745 3.315 3.615
Research & Development 4.944 5.484 0.16 2.938 6.073
Operating Income -7.173 -7.805 -7.051 -9.05 -9.035
Interest Income (Expense), Net Non-Operating -0.363 -0.222 0.606 0.053 -0.146
Other, Net -0.023 0 0.005 0.009 0.042
Net Income Before Taxes -7.559 -8.027 -6.44 -8.988 -9.139
Net Income After Taxes -7.559 -8.027 -6.44 -8.988 -9.139
Net Income Before Extra. Items -7.559 -8.027 -6.44 -8.988 -9.139
Net Income -7.559 -8.027 -6.44 -8.988 -9.139
Income Available to Common Excl. Extra. Items -7.559 -8.027 -6.44 -8.988 -9.139
Income Available to Common Incl. Extra. Items -7.559 -8.027 -6.44 -8.988 -9.139
Diluted Net Income -7.559 -8.027 -6.44 -8.988 -9.139
Diluted Weighted Average Shares 3.10096 2.41058 3.01146 3.01134 2.99739
Diluted EPS Excluding Extraordinary Items -2.43763 -3.3299 -2.1385 -2.98472 -3.04899
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.63241 -3.3299 -1.09382 -2.05589 -3.04899
Unusual Expense (Income) -0.604 0 3.146 2.797 0
Gain (Loss) on Sale of Assets
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 51.43 91.247 42.297 6.106 25.679
Cash and Short Term Investments 50.487 88.756 34.607 5.571 25.512
Cash & Equivalents 50.487 88.756 34.607 5.571 25.512
Total Receivables, Net 0 0.806 5 0.44 0.107
Prepaid Expenses 0.596 1.306 0.352 0.095 0.06
Total Assets 52.79 96.513 47.347 11.886 26.628
Property/Plant/Equipment, Total - Net 0.425 4.437 4.228 4.781 0.017
Property/Plant/Equipment, Total - Gross 1.12 4.954 4.654 5.109 0.295
Accumulated Depreciation, Total -0.695 -0.517 -0.426 -0.328 -0.278
Long Term Investments 0.874 0.723 0.822 0.999 0.932
Total Current Liabilities 6.369 11.296 107.449 26.575 7.355
Accounts Payable 2.72 4.71 5.578 11.239 0.534
Accrued Expenses 1.991 4.113 7.276 3.694 2.98
Notes Payable/Short Term Debt 0 0 51.43 5.848 0
Other Current Liabilities, Total 1.591 2.415 43.165 5.794 3.841
Total Liabilities 9.018 15.006 137.796 30.472 7.717
Total Long Term Debt 0.168 0.235 0.635 0 0
Other Liabilities, Total 2.481 3.475 29.712 3.897 0.362
Total Equity 43.772 81.507 -90.449 -18.586 18.911
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.301 0.3 0.156 0.095 0.094
Additional Paid-In Capital 297.327 296.445 72.136 63.584 60.138
Retained Earnings (Accumulated Deficit) -253.942 -215.135 -160.562 -80.455 -39.797
Treasury Stock - Common 0 -1.846 -1.81 -1.524
Total Liabilities & Shareholders’ Equity 52.79 96.513 47.347 11.886 26.628
Total Common Shares Outstanding 3.0114 2.99591 1.53167 0.99763 0.99763
Other Current Assets, Total 0.347 0.379 2.338
Long Term Debt 0 0.635
Other Equity, Total 0.086 -0.103 -0.333
Other Long Term Assets, Total 0.061 0.106
Current Port. of LT Debt/Capital Leases 0.067 0.058
Capital Lease Obligations 0.168 0.235
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 19.931 26.225 40.627 51.43 56.68
Cash and Short Term Investments 14.841 21.682 29.219 50.487 55.143
Cash & Equivalents 14.841 21.682 29.219 50.487 55.143
Total Receivables, Net 0.102 0.557 9.678 0 0
Prepaid Expenses 3.317 3.368 1.272 0.596 1.11
Other Current Assets, Total 1.671 0.618 0.458 0.347 0.427
Total Assets 30.987 37.619 41.767 52.79 61.316
Property/Plant/Equipment, Total - Net 7.54 7.871 0.126 0.425 3.687
Property/Plant/Equipment, Total - Gross 8.952 9.093 0.126 1.12 4.351
Accumulated Depreciation, Total -1.412 -1.222 0 -0.695 -0.664
Long Term Investments 0.15 0.874 0.874
Other Long Term Assets, Total 3.516 3.523 0.864 0.061 0.075
Total Current Liabilities 11.486 7.597 2.031 6.369 8.182
Accounts Payable 4.406 4.265 0.692 2.72 2.218
Accrued Expenses 5.354 3.3 1.088 1.991 3.804
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.726 0.032 0.251 1.591 2.096
Total Liabilities 17.701 14.062 2.101 9.018 11.106
Total Long Term Debt 0 0 0 0.168 0.186
Long Term Debt
Other Liabilities, Total 6.215 6.465 0.07 2.481 2.738
Total Equity 13.286 23.557 39.666 43.772 50.21
Common Stock 0.084 0.084 0.301 0.301 0.301
Additional Paid-In Capital 146.631 146.221 297.679 297.327 297.109
Retained Earnings (Accumulated Deficit) -133.254 -122.596 -258.479 -253.942 -247.502
Treasury Stock - Common -0.15 -0.15
Other Equity, Total -0.025 -0.002 0.165 0.086 0.302
Total Liabilities & Shareholders’ Equity 30.987 37.619 41.767 52.79 61.316
Total Common Shares Outstanding 8.37027 8.37027 3.01142 3.0114 3.01136
Current Port. of LT Debt/Capital Leases 0 0.067 0.064
Capital Lease Obligations 0.168 0.186
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -38.807 -54.573 -80.107 -40.658 -20.025
Cash From Operating Activities -38.39 -52.643 -22.888 -24.589 -8.02
Cash From Operating Activities 0.178 0.091 0.098 0.05 0.002
Non-Cash Items 4.473 27.809 31.352 6.269 9.051
Cash Taxes Paid 0 0
Cash Interest Paid 0 0.007 0 0
Changes in Working Capital -4.234 -25.97 25.769 9.75 2.952
Cash From Investing Activities 0 -0.382 -0.041 -0.242 0
Capital Expenditures 0 -0.382 -0.041 -0.242 0
Cash From Financing Activities -0.06 107.171 52.409 4.89 31.741
Issuance (Retirement) of Stock, Net 0 -0.617 20.813 -0.375 28.596
Issuance (Retirement) of Debt, Net -0.058 0.293 32.118 5.265 3.145
Net Change in Cash -38.269 54.149 29.036 -19.941 23.721
Financing Cash Flow Items -0.002 107.495 -0.522
Foreign Exchange Effects 0.181 0.003 -0.444
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -4.537 -38.807 -32.367 -23.379 -14.24
Cash From Operating Activities -8.079 -38.39 -33.964 -25.558 -15.653
Cash From Operating Activities 0.022 0.178 0.147 0.063 0.032
Non-Cash Items 1.016 4.473 1.029 1.604 0.179
Changes in Working Capital -4.58 -4.234 -2.773 -3.846 -1.624
Cash From Investing Activities -10 0 0 0 0
Capital Expenditures 0 0 0 0
Cash From Financing Activities -3.268 -0.06 -0.045 -0.028 -0.014
Financing Cash Flow Items -3.025 -0.002 -0.002 0.001 0
Issuance (Retirement) of Stock, Net 0 0 0 0
Issuance (Retirement) of Debt, Net -0.243 -0.058 -0.043 -0.029 -0.014
Foreign Exchange Effects 0.079 0.181 0.396 0.202 -0.087
Net Change in Cash -21.268 -38.269 -33.613 -25.384 -15.754
Cash Interest Paid 0
Other Investing Cash Flow Items, Total -10

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Angion Biomedica Corp. Company profile

About Angion Biomedica Corp

Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).

Industry: Biotechnology & Medical Research (NEC)

451 D Street, 5Th Floor
BOSTON
MASSACHUSETTS 02459
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

Gold

2,392.09 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

BTC/USD

64,737.80 Price
+1.160% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.53 Price
+3.850% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

17,037.80 Price
-1.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading